Yondelis (trabectedin) is a small molecule pharmaceutical. Trabectedin was first approved as Yondelis on 2007-09-17. It is used to treat leiomyosarcoma and liposarcoma in the USA. It has been approved in Europe to treat ovarian neoplasms and sarcoma. It is known to target nuclear receptor subfamily 1 group I member 2. Yondelis's patent is valid until 2028-01-07 (FDA).
|Indication||leiomyosarcoma, liposarcoma, ovarian neoplasms, sarcoma|
|Drug Class||Ecteinascodin derivatives|